About: Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
Creator	Poglitsch, Marko Llorens-Cortes, Catherine Arendse, Lauren Burnett, John Danser, A Ehlers, Mario Sturrock, Edward Touyz, Rhian
source	Medline; PMC
abstract	Despite the success of renin-angiotensin system (RAS) blockade by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT(1)R) blockers, current therapies for hypertension and related cardiovascular diseases are still inadequate. Identification of additional components of the RAS and associated vasoactive pathways, as well as new structural and functional insights into established targets, have led to novel therapeutic approaches with the potential to provide improved cardiovascular protection and better blood pressure control and/or reduced adverse side effects. The simultaneous modulation of several neurohumoral mediators in key interconnected blood pressure–regulating pathways has been an attractive approach to improve treatment efficacy, and several novel approaches involve combination therapy or dual-acting agents. In addition, increased understanding of the complexity of the RAS has led to novel approaches aimed at upregulating the ACE2/angiotensin-(1-7)/Mas axis to counter-regulate the harmful effects of the ACE/angiotensin II/angiotensin III/AT(1)R axis. These advances have opened new avenues for the development of novel drugs targeting the RAS to better treat hypertension and heart failure. Here we focus on new therapies in preclinical and early clinical stages of development, including novel small molecule inhibitors and receptor agonists/antagonists, less conventional strategies such as gene therapy to suppress angiotensinogen at the RNA level, recombinant ACE2 protein, and novel bispecific designer peptides.
has issue date	2019-10-01(xsd:dateTime)
bibo:doi	10.1124/pr.118.017129
bibo:pmid	31537750
has license	cc-by-nc
sha1sum (hex)	45cf4bcdf80e9ed9e3048485b0c57926028451d3
schema:url	https://doi.org/10.1124/pr.118.017129
resource representing a document's title	Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
has PubMed Central identifier	PMC6782023
has PubMed identifier	31537750
schema:publication	Pharmacol Rev
resource representing a document's body	covid:45cf4bcdf80e9ed9e3048485b0c57926028451d3#body_text
is schema:about of	named entity 'Novel' named entity 'THERAPEUTIC' named entity 'ASSOCIATED' named entity 'PEPTIDES' named entity 'NOVEL' named entity 'APPROACHES' named entity 'RENIN-ANGIOTENSIN SYSTEM' named entity 'HYPERTENSION' named entity 'HEART FAILURE' named entity 'TARGETING' named entity 'Hypertension' named entity 'Peptides' named entity 'Heart Failure' named entity 'angiotensinogen' named entity 'protein' named entity 'endothelins' named entity 'composite endpoint' named entity 'heart failure' named entity 'pulmonary arterial hypertension' named entity 'active site' named entity 'Adverse effects' named entity 'ACE' named entity 'glycosylation' named entity 'serum' named entity 'high molecular weight' named entity 'phase III clinical trials' named entity 'heart failure' named entity 'dipeptidase' named entity 'G-protein signaling' named entity 'angiotensin-converting enzyme 2' named entity 'hypertension' named entity 'substrates' named entity 'renin' named entity 'omapatrilat' named entity 'centrally acting' named entity 'GalNAc' named entity 'heart failure' named entity 'angioedema' named entity 'reduced blood pressure' named entity 'ambrisentan' named entity 'amino-acid' named entity 'chronic heart failure' named entity 'metabolizing' named entity 'apoptosis' named entity 'guanylyl cyclase' named entity 'substrates' named entity 'protein' named entity 'hyperactivity' named entity 'family of proteins' named entity 'RAS' named entity 'Somatic' named entity 'angioedema' named entity 'EC 3.4.11.2' named entity 'Ang II' named entity 'angiotensin' named entity 'second-messenger' named entity 'binding affinity' named entity 'antifibrotic' named entity 'mesangial cells' named entity 'angiotensin' named entity 'Crystal structures' named entity 'peptides' named entity 'Ang II' named entity 'developed and tested' named entity 'lowered blood pressure' named entity 'site-directed mutagenesis' named entity 'kDa' named entity 'peptide' named entity 'African Americans' named entity 'ACE inhibitor' named entity 'secretion' named entity 'recombinant' named entity 'hypertension' named entity 'testis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software